CTNI-32. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Aoki, Tomokazu, Arakawa, Yoshiki, Ueba, Tetsuya, Oda, Masashi, Nishida, Namiko, Akiyama, Yukinori, Iwasaki, Koichi, Mikuni, Nobuhiro, Miyamoto, Susumu
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650486/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.199
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars